Melanoma Clinical Practice Guidelines in OncologyNCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.In 2008, an estimated 62,480 new cases of melanoma will have been diagnosed and approximately 8420 patients will have died of the disease in the United States.1 However, these projections for new cases may represent a substantial underestimation, because many superficial and in situ melanomas treated in the outpatient setting are not reported. The incidence of melanoma continues to increase dramatically. Melanoma is increasing in men more rapidly than any other malignancy and more rapidly in women than any other malignancy except lung cancer. For someone born in the United States in 2005, the lifetime risk for developing melanoma may be as high as 1 in 55.2 Melanoma ranks second to adult leukemia in terms of loss of years of potential life, per death. The median age at diagnosis is 59 years.Risk factors for melanoma include...

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008;58:7196.

  • 2

    Surveillance Epidemiology and End Results. SEER stats fact sheet. Available at: http://seer.cancer.gov/statfacts/html/melan. html#ref11. Accessed 8 December 2008.

    • Search Google Scholar
    • Export Citation
  • 3

    Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. N Engl J Med 2003;349:22332240.

  • 4

    Rigel DS, Rivers JK, Kopf AW. Dysplastic nevi. Markers for increased risk for melanoma. Cancer 1989;63:386389.

  • 5

    Ivry GB, Ogle CA, Shim EK. Role of sun exposure in melanoma. Dermatol Surg 2006;32:481492.

  • 6

    Jensen EH, Margolin KA, Sondak VK. Melanoma and other skin cancers. In: Pazdur R, Coia L, Hoskins WJ, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach, 9th edition. New York: CMP Media; 2005:531562.

    • Search Google Scholar
    • Export Citation
  • 7

    Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351:9981012.

  • 8

    Balch CM, Buzaid AC, Soong SJ. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:36353648.

    • Search Google Scholar
    • Export Citation
  • 9

    Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Manual, 6th ed. New York: Springer-Verlag; 2002.

  • 10

    Balch CM, Soong SJ, Gershenwald JE. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:36223634.

    • Search Google Scholar
    • Export Citation
  • 11

    Barnhill RL, Katzen J, Spatz A. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 2005;32:268273.

    • Search Google Scholar
    • Export Citation
  • 12

    Azzola MF, Shaw HM, Thompson JF. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003;97:14881498.

    • Search Google Scholar
    • Export Citation
  • 13

    Francken AB, Shaw HM, Thompson JF. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 2004;11:426433.

    • Search Google Scholar
    • Export Citation
  • 14

    Gimotty PA, Elder DE, Fraker DL. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007;25:11291134.

    • Search Google Scholar
    • Export Citation
  • 15

    Paek SC, Griffith KA, Johnson TM. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 2007;109:100108.

    • Search Google Scholar
    • Export Citation
  • 16

    Sondak VK, Taylor JM, Sabel MS. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004;11:247258.

    • Search Google Scholar
    • Export Citation
  • 17

    Sober AJ, Chuang TY, Duvic M. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001;45:579586.

  • 18

    Neuman HB, Patel A, Ishill N. A single-institution validation of the AJCC staging system for stage IV melanoma. Ann Surg Oncol 2008;15:20342041.

    • Search Google Scholar
    • Export Citation
  • 19

    Cascinelli N, Belli F, Santinami M. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000;7:469474.

    • Search Google Scholar
    • Export Citation
  • 20

    Buzaid AC, Sandler AB, Mani S. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993;11:638643.

  • 21

    Wang TS, Johnson TM, Cascade PN. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. J Am Acad Dermatol 2004;51:399405.

    • Search Google Scholar
    • Export Citation
  • 22

    Yancovitz M, Finelt N, Warycha MA. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. Cancer 2007;110:11071114.

    • Search Google Scholar
    • Export Citation
  • 23

    Aloia TA, Gershenwald JE, Andtbacka RH. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol 2006;24:28582865.

    • Search Google Scholar
    • Export Citation
  • 24

    Gold JS, Jaques DP, Busam KJ. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 2007;14:21332140.

    • Search Google Scholar
    • Export Citation
  • 25

    Miranda EP, Gertner M, Wall J. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg 2004;139:831836; discussion 836–837.

    • Search Google Scholar
    • Export Citation
  • 26

    Buzaid AC, Tinoco L, Ross MI. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol 1995;13:21042108.

    • Search Google Scholar
    • Export Citation
  • 27

    Johnson TM, Fader DJ, Chang AE. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. Ann Surg Oncol 1997;4:396402.

    • Search Google Scholar
    • Export Citation
  • 28

    Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. Ann Surg Oncol 1997;4:252258.

  • 29

    Clark PB, Soo V, Kraas J. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg 2006;141:284288.

    • Search Google Scholar
    • Export Citation
  • 30

    Maubec E, Lumbroso J, Masson F. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. Melanoma Res 2007;17:147154.

    • Search Google Scholar
    • Export Citation
  • 31

    Wagner JD, Schauwecker D, Davidson D. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005;104:570579.

    • Search Google Scholar
    • Export Citation
  • 32

    Brady MS, Akhurst T, Spanknebel K. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol 2006;13:525532.

    • Search Google Scholar
    • Export Citation
  • 33

    National Institutes of Health. After treatment of early melanoma, should patients and family members be followed? Why and How? NIH Consensus Statement 1992;10:126.

    • Search Google Scholar
    • Export Citation
  • 34

    Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991;126:438441.

  • 35

    Veronesi U, Cascinelli N, Adamus J. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988;318:11591162.

    • Search Google Scholar
    • Export Citation
  • 36

    Balch CM, Soong SJ, Smith T. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001;8:101108.

    • Search Google Scholar
    • Export Citation
  • 37

    Balch CM, Urist MM, Karakousis CP. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 1993;218:262267; discussion 267–269.

    • Search Google Scholar
    • Export Citation
  • 38

    Cohn-Cedermark G, Rutqvist LE, Andersson R. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000;89:14951501.

    • Search Google Scholar
    • Export Citation
  • 39

    Khayat D, Rixe O, Martin G. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003;97:19411946.

    • Search Google Scholar
    • Export Citation
  • 40

    Thomas JM, Newton-Bishop J, A’Hern R. Excision margins in high-risk malignant melanoma. N Engl J Med 2004;350:757766.

  • 41

    Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. Can J Surg 2003;46:419426.

    • Search Google Scholar
    • Export Citation
  • 42

    Johnson TM, Headington JT, Baker SR, Lowe L. Usefulness of the staged excision for lentigo maligna and lentigo maligna melanoma: the ”square” procedure. J Am Acad Dermatol 1997;37:758764.

    • Search Google Scholar
    • Export Citation
  • 43

    Zitelli JA, Brown C, Hanusa BH. Mohs micrographic surgery for the treatment of primary cutaneous melanoma. J Am Acad Dermatol 1997;37:236245.

    • Search Google Scholar
    • Export Citation
  • 44

    Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. Dermatol Surg 2008;34:147151.

  • 45

    Naylor MF, Crowson N, Kuwahara R. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003;149(Suppl 66):6670.

  • 46

    Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. Clin Exp Dermatol 2004;29:1521.

    • Search Google Scholar
    • Export Citation
  • 47

    Spenny ML, Walford J, Werchniak AE. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. Cutis 2007;79:149152.

    • Search Google Scholar
    • Export Citation
  • 48

    Johnson TM, Sondak VK, Bichakjian CK, Sabel MS. The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol 2006;54:1927.

    • Search Google Scholar
    • Export Citation
  • 49

    Morton DL, Cochran AJ, Thompson JF. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005;242:302311; discussion 311–303.

    • Search Google Scholar
    • Export Citation
  • 50

    Morton DL, Thompson JF, Cochran AJ. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:13071317.

  • 51

    Thompson JF, Shaw HM. Sentinel node mapping for melanoma: results of trials and current applications. Surg Oncol Clin N Am 2007;16:3554.

  • 52

    Wright BE, Scheri RP, Ye X. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg 2008;143:892899; discussion 899–900.

    • Search Google Scholar
    • Export Citation
  • 53

    Bleicher RJ, Essner R, Foshag LJ. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003;21:13261331.

  • 54

    Ranieri JM, Wagner JD, Wenck S. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol 2006;13:927932.

  • 55

    Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol 2006;13:302309.

  • 56

    Ferrone CR, Panageas KS, Busam K. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 2002;9:637645.

    • Search Google Scholar
    • Export Citation
  • 57

    Gershenwald JE, Mansfield PF, Lee JE, Ross MI. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma. Ann Surg Oncol 2000;7:160165.

    • Search Google Scholar
    • Export Citation
  • 58

    Gutzmer R, Satzger I, Thoms KM. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas. J Dtsch Dermatol Ges 2008;6:198203.

    • Search Google Scholar
    • Export Citation
  • 59

    Edwards MJ, Martin KD, McMasters KM. Lymphatic mapping and sentinel lymph node biopsy in the staging of melanoma. Surg Oncol 1998;7:5157.

  • 60

    Glass FL, Cottam JA, Reintgen DS, Fenske NA. Lymphatic mapping and sentinel node biopsy in the management of high-risk melanoma. J Am Acad Dermatol 1998;39:603610.

    • Search Google Scholar
    • Export Citation
  • 61

    Kang JC, Wanek LA, Essner R. Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol 2005;23:47644770.

    • Search Google Scholar
    • Export Citation
  • 62

    Morton DL, Thompson JF, Essner R. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999;230:453463; discussion 463–465.

    • Search Google Scholar
    • Export Citation
  • 63

    Fontaine D, Parkhill W, Greer W, Walsh N. Partial regression of primary cutaneous melanoma: is there an association with subclinical sentinel lymph node metastasis? Am J Dermatopathol 2003;25:371376.

    • Search Google Scholar
    • Export Citation
  • 64

    Morris KT, Busam KJ, Bero S. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol 2008;15:316322.

    • Search Google Scholar
    • Export Citation
  • 65

    Coit DG. Extent of groin dissection for melanoma. Surg Clin North Am 1992;1:271280.

  • 66

    Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. Arch Surg 1989;124:162166.

  • 67

    Shen P, Conforti AM, Essner R. Is the node of Cloquet the sentinel node for the iliac/obturator node group? Cancer J 2000;6:9397.

  • 68

    Cascinelli N, Bombardieri E, Bufalino R. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. J Clin Oncol 2006;24:44644471.

    • Search Google Scholar
    • Export Citation
  • 69

    Lee JH, Essner R, Torisu-Itakura H. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 2004;22:36773684.

    • Search Google Scholar
    • Export Citation
  • 70

    Cascinelli N, Belli F, MacKie RM. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 2001;358:866869.

    • Search Google Scholar
    • Export Citation
  • 71

    Grob JJ, Dreno B, de la Salmoniere P. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998;351:19051910.

    • Search Google Scholar
    • Export Citation
  • 72

    Pehamberger H, Soyer HP, Steiner A. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998;16:14251429.

    • Search Google Scholar
    • Export Citation
  • 73

    Hancock BW, Wheatley K, Harris S. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 2004;22:5361.

    • Search Google Scholar
    • Export Citation
  • 74

    Eggermont AM, Suciu S, MacKie R. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005;366:11891196.

    • Search Google Scholar
    • Export Citation
  • 75

    Kirkwood JM, Strawderman MH, Ernstoff MS. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 1996;14:717.

    • Search Google Scholar
    • Export Citation
  • 76

    Kirkwood JM, Ibrahim JG, Sondak VK. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000;18:24442458.

    • Search Google Scholar
    • Export Citation
  • 77

    Kirkwood JM, Ibrahim JG, Sosman JA. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:23702380.

    • Search Google Scholar
    • Export Citation
  • 78

    Gogas H, Ioannovich J, Dafni U. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709718.

    • Search Google Scholar
    • Export Citation
  • 79

    Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002;20:18181825.

    • Search Google Scholar
    • Export Citation
  • 80

    Kirkwood JM, Manola J, Ibrahim J. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:16701677.

    • Search Google Scholar
    • Export Citation
  • 81

    Verma S, Quirt I, McCready D. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 2006;106:14311442.

    • Search Google Scholar
    • Export Citation
  • 82

    Gray RJ, Pockaj BA, Kirkwood JM. An update on adjuvant interferon for melanoma. Cancer Control 2002;9:1621.

  • 83

    Hauschild A, Gogas H, Tarhini A. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008;112:982994.

    • Search Google Scholar
    • Export Citation
  • 84

    Hurley KE, Chapman PB. Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b. Oncologist 2005;10:739742.

    • Search Google Scholar
    • Export Citation
  • 85

    Bonnen MD, Ballo MT, Myers JN. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer 2004;100:383389.

    • Search Google Scholar
    • Export Citation
  • 86

    Strom EA, Ross MI. Adjuvant radiation therapy after axillary lymphadenectomy for metastatic melanoma: toxicity and local control. Ann Surg Oncol 1995;2:445449.

    • Search Google Scholar
    • Export Citation
  • 87

    Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 2005;6:185193.

  • 88

    Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748759.

    • Search Google Scholar
    • Export Citation
  • 89

    Houghton AN, Coit DG, Daud A. NCCN Clinical Practice Guidelines in Oncology: Melanoma. J Natl Compr Canc Netw 2006;4:666684.

  • 90

    Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19:2134.

    • Search Google Scholar
    • Export Citation
  • 91

    Middleton MR, Grob JJ, Aaronson N. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158166.

    • Search Google Scholar
    • Export Citation
  • 92

    Legha SS, Ring S, Papadopoulos N. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 1989;64:20242029.

    • Search Google Scholar
    • Export Citation
  • 93

    McClay EF, Mastrangelo MJ, Bellet RE, Berd D. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma. Cancer Treat Rep 1987;71:465469.

    • Search Google Scholar
    • Export Citation
  • 94

    Chapman PB, Einhorn LH, Meyers ML. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:27452751.

    • Search Google Scholar
    • Export Citation
  • 95

    Agarwala SS, Keilholz U, Hogg D. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma [abstract]. J Clin Oncol 2007;25(Supp 1):Abstract 8510.

    • Search Google Scholar
    • Export Citation
  • 96

    Rao RD, Holtan SG, Ingle JN. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer 2006;106:375382.

    • Search Google Scholar
    • Export Citation
  • 97

    Atkins MB, Lotze MT, Dutcher JP. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:21052116.

    • Search Google Scholar
    • Export Citation
  • 98

    Smith FO, Downey SG, Klapper JA. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008;14:56105618.

    • Search Google Scholar
    • Export Citation
  • 99

    Legha SS, Ring S, Bedikian A. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Ann Oncol 1996;7:827835.

    • Search Google Scholar
    • Export Citation
  • 100

    Legha SS, Ring S, Eton O. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998;16:17521759.

    • Search Google Scholar
    • Export Citation
  • 101

    Eton O, Legha SS, Bedikian AY. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:20452052.

    • Search Google Scholar
    • Export Citation
  • 102

    Atkins MB, Hsu J, Lee S. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic, malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2008;26:57485754.

    • Search Google Scholar
    • Export Citation
  • 103

    Bajetta E, Del Vecchio M, Nova P. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol 2006;17:571577.

    • Search Google Scholar
    • Export Citation
  • 104

    Keilholz U, Punt CJ, Gore M. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005;23:67476755.

    • Search Google Scholar
    • Export Citation
  • 105

    Ridolfi R, Chiarion-Sileni V, Guida M. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol 2002;20:16001607.

    • Search Google Scholar
    • Export Citation
  • 106

    Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 2007;25:54265434.

    • Search Google Scholar
    • Export Citation
  • 107

    Yao KA, Hsueh EC, Essner R. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg 2003;238:743747.

    • Search Google Scholar
    • Export Citation
  • 108

    Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. J Dermatol Surg Oncol 1993;19:985990.

    • Search Google Scholar
    • Export Citation
  • 109

    Wolf IH, Richtig E, Kopera D, Kerl H. Locoregional cutaneous metastases of malignant melanoma and their management. Dermatol Surg 2004;30:244247.

    • Search Google Scholar
    • Export Citation
  • 110

    Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004;88:13.

    • Search Google Scholar
    • Export Citation
  • 111

    Fraker DL, Coit DG. Isolated perfusion of extremity tumors. Regional therapy of advanced cancer. 1997:333350.

  • 112

    Lens MB, Dawes M. Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol 2003;4:359364.

    • Search Google Scholar
    • Export Citation
  • 113

    Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127136.

    • Search Google Scholar
    • Export Citation
  • 114

    Allen PJ, Coit DG. The surgical management of metastatic melanoma. Ann Surg Oncol 2002;9:762770.

  • 115

    Ferrone CR, Ben Porat L, Panageas KS. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005;294:16471654.

    • Search Google Scholar
    • Export Citation
  • 116

    Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 1990;212:173177.

  • 117

    Fawzy FI, Fawzy NW, Hyun CS. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993;50:681689.

    • Search Google Scholar
    • Export Citation
  • 118

    Gutman M, Cnaan A, Inbar M. Are malignant melanoma patients at higher risk for a second cancer? Cancer 1991;68:660665.

  • 119

    Kang S, Barnhill RL, Mihm MC Jr, Sober AJ. Multiple primary cutaneous melanomas. Cancer 1992;70:19111916.

  • 120

    Rhodes AR. Public education and cancer of the skin. What do people need to know about melanoma and nonmelanoma skin cancer? Cancer 1995;75:613636.

    • Search Google Scholar
    • Export Citation
  • 121

    Basseres N, Grob JJ, Richard MA. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology 1995;191:199203.

    • Search Google Scholar
    • Export Citation
  • 122

    Weiss M, Loprinzi CL, Creagan ET. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA 1995;274:17031705.

    • Search Google Scholar
    • Export Citation
  • 123

    Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. N Engl J Med 2007;357:22772284.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 392 229 20
PDF Downloads 230 161 13
EPUB Downloads 0 0 0